The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 28, 2011

Filed:

Jan. 25, 2006
Applicants:

Oren Becker, Mevaseret Zion, IL;

Rosa Melendez, Woburn, MA (US);

Yael Marantz, Kadima, IL;

Anurag Sharadendu, Bedford, MA (US);

Merav Fichman, Modi'in, IL;

Mercedes Lobera, Concord, MA (US);

Hanoch Senderowitz, Tel Aviv, IL;

Srinivasa Rao Cheruku, Lexington, MA (US);

Silvia Noiman, Herzliya, IL;

Xiang Y. Yu, Acton, MA (US);

Sharon Shacham, Newton, MA (US);

Laurence Wu, Tainan, TW;

Ashis Saha, Stow, MA (US);

Pini Orbach, Needham, MA (US);

Dale S. Dhanoa, Delmar, CA (US);

Inventors:

Oren Becker, Mevaseret Zion, IL;

Rosa Melendez, Woburn, MA (US);

Yael Marantz, Kadima, IL;

Anurag Sharadendu, Bedford, MA (US);

Merav Fichman, Modi'in, IL;

Mercedes Lobera, Concord, MA (US);

Hanoch Senderowitz, Tel Aviv, IL;

Srinivasa Rao Cheruku, Lexington, MA (US);

Silvia Noiman, Herzliya, IL;

Xiang Y. Yu, Acton, MA (US);

Sharon Shacham, Newton, MA (US);

Laurence Wu, Tainan, TW;

Ashis Saha, Stow, MA (US);

Pini Orbach, Needham, MA (US);

Dale S. Dhanoa, Delmar, CA (US);

Assignee:

Galenea Corp., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 295/135 (2006.01); A61K 31/451 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention relates to 5-HTreceptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and type II diabetes; and psychological disorders such as schizophrenia, are disclosed.


Find Patent Forward Citations

Loading…